SPERO THERAPEUTICS INC. - COMMON STOCK

Spero Therapeutics Provides Corporate Update and 2024 Outlook

05 Jan 2024 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

02 Jan 2024 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update

13 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

06 Nov 2023 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Present at Upcoming November Investor Conferences

01 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

01 Nov 2023 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

29 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Present at Cantor’s Global Healthcare 2023 Investor Conference

20 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

06 Sep 2023 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update

10 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

03 Aug 2023 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr

31 Jul 2023 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer

14 Jun 2023 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 May 2023 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update

11 May 2023 15:05:01 By Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

04 May 2023 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

28 Apr 2023 15:05:00 By Nasdaq GlobeNewswire